ACM
CTMX icon

Altium Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Altium Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-467,491
Closed -$482K – 40
2024
Q4 		$482K Sell
467,491
-447,509
-49% -$481K 0.14% 60
2024
Q3 		$1.08M Buy
+915,000
New +$1.16M 0.32% 48
2022
Q2 		– Sell
-663,800
Closed -$1.77M – 132
2022
Q1 		$1.77M Hold
663,800
– – 0.59% 62
2021
Q4 		$2.87M Sell
663,800
-569,842
-46% -$3.34M 0.79% 54
2021
Q3 		$6.28M Buy
1,233,642
+371,225
+43% +$1.99M 1.65% 11
2021
Q2 		$5.46M Buy
862,417
+379,376
+79% +$2.95M 1.27% 24
2021
Q1 		$3.73M Buy
483,041
+209,338
+76% +$1.66M 1.04% 36
2020
Q4 		$1.79M Buy
+273,703
New +$1.96M 0.67% 70

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Altium Capital Management's CTMX Position: Q1 2025 in Review

Altium Capital Management sold out of CytomX Therapeutics (CTMX) in Q1 2025, closing a stake of 467,491 shares — an estimated $482K sold.

Altium Capital Management first reported a position in CTMX in Q4 2020 and held it in 8 quarters. The position peaked at $6.28M in Q3 2021. 66 funds tracked by Wall St. Rank hold CTMX as of Q1 2025.

  • Altium Capital Management reported no remaining CytomX Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 467,491 CytomX Therapeutics shares in Q1 2025, an estimated $482K.
  • Altium Capital Management first reported a position in CytomX Therapeutics in Q4 2020 and held it in 8 quarters.
  • Altium Capital Management's CytomX Therapeutics position peaked at $6.28M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.